Developing A NextGen RNA Therapy for Rett Syndrome
December 16, 2020
David Huss, PhD, VP, Head of Research for Shape Therapeutics discusses the company's proprietary RNA technologies and how they will be applied to fix MECP2 mutations, the root cause of Rett syndrome.
